Skip to main content

Abeona Therapeutics Inc.

corporate_fare Company Profile

Abeona Therapeutics Inc.

ABEO·NASDAQ·Life Sciences·CIK 0000318306

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration (FDA) approved ZEVASKYN ® (prademagene zamikeracel) gene-modified cellular sheets, also known as ZEVASKYN ® , as the first and only autologous cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. ZEVASKYN ® is the only FDA-approved product to treat RDEB wounds with a single surgical application and was granted Orphan Drug and Rare Pediatric Disease designations by the FDA. ZEVASKYN ® is manufactured at the company's current Good Manufacturing Practices (cGMP) facility in Cleveland, Ohio. Treatments are provided through ZEVASKYN ® qualified treatment centers, a network selected for their expertise in cell and gene therapy and trained to administer ZEVASKYN ® . As of March 2026, Abeona has activated 4 qualified treatment centers and is expanding this network. The company's development portfolio also includes adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids. Abeona partners with academic researchers, patient advocacy organizations, caregivers, and other biotechnology companies to develop therapies for rare genetic diseases lacking effective treatment options. The company's strategy involves commercializing ZEVASKYN ® and advancing and commercializing its cell and gene therapy programs.

Abeona Therapeutics Inc. (NASDAQ:ABEO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ABEO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders to Vote on Significant Equity Plan Expansion and Governance Amendment
  • Abeona Therapeutics Appoints Experienced Biotech CFO Keith Goldan to Board, Chairs Audit Committee
  • Abeona Expands ZEVASKYN Access with New York Treatment Center Activation
  • Abeona Therapeutics Amends Bylaws, Increases Shareholder Meeting Quorum to 50%
  • Abeona Therapeutics Reports 2025 Annual Results, Driven by PRV Sale & ZEVASKYN Commercial Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5.82M
Net Income
$71.18M
Diluted EPS
$1.01
Op. Cash Flow
-$76.33M
Free Cash Flow
-$84.3M
Gross Profit
$4.29M
Operating Income
-$89.45M
Cash & Equivalents
$78.44M
Total Debt
$20.04M
Debt / Equity
0.13×
Net Margin
12.23×
Shares Outstanding
55.04M sh
Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010413
$2.42
52-week range · as of 2026-11-09 $2.3 – $7.65
Market cap
$138.3M
Volume
4.7M (2.3× avg)
3-mo avg 2.1M
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABEO - Filings & News (Page 2)

ABEO
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $5.50
Real-time Price: $2.42 info
Change: -$3.08 (-56%) info
Market Cap: $138.295M info
ABEO
Apr 07, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.76
Real-time Price: $2.42 info
Change: -$2.34 (-49%) info
Market Cap: $138.295M info
ABEO
Apr 02, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.58
Real-time Price: $2.42 info
Change: -$2.16 (-47%) info
Market Cap: $138.295M info
ABEO
Mar 20, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $2.42 info
Change: -$2.03 (-46%) info
Market Cap: $138.295M info
ABEO
Mar 17, 2026, 7:36 AM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.88
Real-time Price: $2.42 info
Change: -$2.46 (-50%) info
Market Cap: $138.295M info
ABEO
Mar 17, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.02
Real-time Price: $2.42 info
Change: -$2.60 (-52%) info
Market Cap: $138.295M info
ABEO
Mar 09, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.85
Real-time Price: $2.42 info
Change: -$2.43 (-50%) info
Market Cap: $138.295M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets